Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: LY2495655
Drug: Placebo
Drug: Standard of Care Chemotherapy

First Posted Date: 2012-01-06

Last Posted Date: 2019-09-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 125

Registration Number: NCT01505530

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cardiff, South Glamorgan, United Kingdom

A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis

Phase 2

Completed

Conditions: Psoriasis
Skin Diseases
Skin Diseases, Papulosquamous

Interventions: Drug: Placebo
Drug: Baricitinib

First Posted Date: 2011-12-13

Last Posted Date: 2019-09-27

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 271

Registration Number: NCT01490632

Locations: 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Carolina, Puerto Rico

On Open-Label Study in Participants With Systemic Lupus Erythematosus

Phase 3

Terminated

Conditions: Autoimmune Disease
Connective Tissue Disease
Systemic Lupus Erythematosus

Interventions: Drug: LY2127399
Drug: Placebo

First Posted Date: 2011-12-08

Last Posted Date: 2018-05-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 1518

Registration Number: NCT01488708

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician, Irving, Texas, United States

A Long-Term Study in Schizophrenia

Phase 3

Terminated

Conditions: Schizophrenia

Interventions: Drug: Pomaglumetad methionil

First Posted Date: 2011-12-07

Last Posted Date: 2013-01-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 282

Registration Number: NCT01487083

Locations: 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Malmo, Sweden

A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension

Phase 1

Completed

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Tadalafil- Tablet or Oral suspension

First Posted Date: 2011-12-02

Last Posted Date: 2019-10-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 20

Registration Number: NCT01484431

Locations: 🇺🇸
Children's Heathcare of Atlanta, Inc. at Egleston, Atlanta, Georgia, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Riley Hospital for Children, Indianapolis, Indiana, United States

and more 4 locations

A Study in Participants With Type 1 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: LY2605541
Drug: Glargine
Drug: Insulin Lispro

First Posted Date: 2011-11-30

Last Posted Date: 2018-04-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 455

Registration Number: NCT01481779

Locations: 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Petersburg, Russian Federation

A Study to Compare the Pharmacokinetics and Pharmacodynamics of LY2963016 to Lantus in Healthy Participants

Phase 1

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Lantus
Drug: LY2963016

First Posted Date: 2011-11-22

Last Posted Date: 2014-10-07

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 80

Registration Number: NCT01476345

Locations: 🇿🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bloemfontein, South Africa

A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease

Phase 2

Completed

Conditions: Sickle Cell Disease

Interventions: Drug: Prasugrel

First Posted Date: 2011-11-22

Last Posted Date: 2014-02-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 33

Registration Number: NCT01476696

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pittsburgh, Pennsylvania, United States

A First-in-Human Study of LY3009385 in Healthy Participants

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: LY3009385
Drug: Placebo

First Posted Date: 2011-11-22

Last Posted Date: 2014-10-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 40

Registration Number: NCT01477567

Locations: 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Singapore, Singapore

Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Insulin Aspart
Drug: Insulin Lispro

First Posted Date: 2011-11-18

Last Posted Date: 2014-03-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 122

Registration Number: NCT01474538

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt Lake City, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy